A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure

Summary

This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitizing mutations who have failed EGFR-TKI therapy. The study includes a dose escalation phase and an expansion phase.

Timeline

Start

2026-10-15

Primary completion

2027-12-30

Completion

2029-12-30

Drugs

Indications